肿瘤免疫微环境可预测口咽鳞癌放疗后复发
该回顾性队列分析84例口咽鳞状细胞癌(OPSCC)患者治疗前活检组织,通过组织病理学、免疫组化(IHC)和转录组分析全面刻画肿瘤免疫微环境(TIME),发现无复发患者TIME富集B/T淋巴细胞、树突状细胞和NK细胞,复发肿瘤中性粒细胞浸润更高;基于转录组构建的14基因免疫特征复发评分(ISRS)对复发具有高预测准确性并优于传统临床预测因子,外部验证支持其预后相关性。
要点
- 无复发OPSCC患者TIME富集B/T淋巴细胞、树突状细胞和NK细胞,复发者中性粒细胞浸润更高。
- IHC标志物CD3、CD8、CD20、FOXP3和PD-L1与无复发生存期(RFS)改善显著相关。
- 14基因免疫特征复发评分(ISRS)预测复发准确性高,优于传统临床预测因子。
核心结论
- 富含淋巴细胞的TIME具有预后意义,14基因免疫特征在预测OPSCC复发方面优于传统标志物。
研究设计与样本
- 回顾性队列分析84例OPSCC患者治疗前肿瘤活检组织,采用组织病理学评估、免疫组化和NanoString nCounter PanCancer Immune Profiling Panel转录组分析。
- 将肿瘤浸润淋巴细胞密度、免疫标志物表达和基因表达特征与临床结局进行关联分析。
- 使用已发表的OPSCC数据集进行外部验证,但因缺乏复发数据仅为间接验证。
主要发现
- 无复发患者TIME富集B和T淋巴细胞、树突状细胞及NK细胞,复发肿瘤中性粒细胞浸润更高。
- IHC标志物CD3、CD8、CD20、FOXP3和PD-L1与RFS改善显著相关。
- 转录组分析确认上述发现并构建14基因免疫特征复发评分(ISRS),对复发具有高预测准确性且优于传统临床预测因子。
- 外部验证支持ISRS对总生存的预后相关性及跨独立队列的稳健性,但属间接验证。
关键数值与推荐
- ISRS为基于转录组分析的14基因免疫特征复发评分。
- IHC标志物CD3、CD8、CD20、FOXP3和PD-L1与RFS改善显著相关。
临床怎么用
- 可将免疫基因特征整合入常规临床实践以细化风险分层并指导个体化治疗。
- 治疗前活检的TIME评估(淋巴细胞浸润密度、免疫标志物表达)有助于识别治疗失败高风险患者。
局限性
- 为探索性研究,样本量84例,属回顾性队列。
- 外部验证因缺乏复发数据仅为间接验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oropharyngeal squamous cell carcinoma (OPSCC), is a distinct subset of head and neck squamous cell carcinomas, with an increasing incidence largely due to HPV infection. Despite established treatments such as cisplatin-based chemoradiotherapy or cetuximab-RT, outcomes remain poor for advanced cases, with high recurrence rates. There is an urgent need for predictive biomarkers to inform treatment decisions and identify patients at risk of treatment failure. MATERIALS AND METHODS: In a retrospective cohort, we analyzed pre-treatment tumor biopsies from 84 OPSCC patients. We conducted comprehensive profiling of the tumor immune microenvironment (TIME) using histopathological evaluation, immunohistochemistry (IHC), and transcriptomic analysis via the NanoString nCounter® PanCancer Immune Profiling Panel. We correlated tumor-infiltrating lymphocyte density, immune marker expression, and gene expression signatures with clinical outcomes. RESULTS: Patients without recurrence had a TIME enriched with B and T lymphocytes, dendritic cells, and NK cells. Recurrent tumors showed higher neutrophil infiltration. IHC markers including CD3, CD8, CD20, FOXP3, and PD-L1 were significantly associated with improved RFS. Transcriptomic analysis confirmed these findings and enabled the development of a 14-gene Immune Signature Recurrence Score (ISRS). The ISRS achieved high predictive accuracy for recurrence and outperformed conventional clinical predictors. External validation using a published OPSCC dataset supported the prognostic relevance of the ISRS for overall survival and its robustness across independent cohorts, although this represents an indirect validation due to the lack of recurrence data. CONCLUSION: This exploratory study highlights the prognostic significance of a robust lymphocyte-rich TIME and introduces a clinically relevant 14-gene immune signature that outperforms traditional markers in predicting recurrence in OPSCC. These results suggest that integrating immune gene signatures into routine clinical practice could refine risk stratification and guide personalized therapy.
引用
- Beltzung F, Biau J, Pereira B, et al. Tumor immune microenvironment predicts recurrence after radiotherapy in oropharyngeal squamous cell carcinoma. Radiother Oncol. 2026. PMID: 42235796. doi:10.1016/j.radonc.2026.111620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。